Xconomy’s Digital Events →
With the backdrop of Biogen’s BLA filing, and the FDA’s expected response for aducanumab in Alzheimer’s disease in 2020, the link between efficacy and approval seems to have broken. Conditional FDA... Read more »
From Our Editors · Podcast
The AI, Big Data, and R&D Boom
From Our Partners · Special Report
Advice for funding and future transformational opportunities
Sponsored · Webinar
Provide an in vitro drug-induced proarrhythmia assessment & strengthen pharmacological safety profiles of drug candidates
© 2007-2022, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.